Linessa

Quick links to important sections

Linessa

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Linessa

Property Description
Active Ingredients Desogestrel, Ethinylestradiol
Form Tablet (Oral Contraceptive Pill)
Pharmacological Class Combined Oral Contraceptive (COC), Hormonal Contraceptive
Common Use Prevention of pregnancy (Contraception)
Origin Synthetic Steroid

Defining Linessa and its Classification

Linessa is defined as a prescription-only Combined Oral Contraceptive (COC), a specific type of medication that is clinically recognized for achieving systemic hormonal regulation. This synthetic steroid preparation is classified within the ATC group G03A (Progestogens and Estrogens, fixed combinations). The drug entity is supplied as a compact tablet intended for oral administration, placing it within the category of oral contraceptive pills. Linessa is structurally a combination drug, which is why it integrates both a progestin and an estrogen component to manage fertility.

Composition: Desogestrel, Ethinylestradiol, and Differentiation

The identity of Linessa hinges on its two active ingredients: the progestin Desogestrel and the estrogen Ethinylestradiol. Desogestrel is specifically recognized as a third-generation progestogen, a feature that differentiates it from older COCs containing progestins like levonorgestrel. Both of these chemical substances are entirely synthetic in origin, designed to modulate the body's natural endocrine system. These active ingredients are incorporated into solid oral excipients to form the final tablet preparation, which ensures consistency in delivery for hormonal regulation.

What is the General Purpose of Linessa?

The general and sole therapeutic purpose of Linessa is the effective prevention of pregnancy (contraception) in women of reproductive potential. This medication primarily works by stopping the release of an egg from the ovary, which serves as a contraceptive method. For instance, Linessa is typically used by individuals seeking a continuous, reversible method of contraception that relies on a daily oral regimen. The blend of the estrogen and progestin components is utilized for this purpose, providing fertility control through multifaceted hormonal regulation.

What side effects are possible with Linessa?

Possible Side Effects and Safety Information

The safety profile for Linessa (Desogestrel and Ethinylestradiol) is formally documented in regulatory sources, classifying adverse events by frequency and the body system affected. This classification helps in understanding the predictable occurrence of various effects.

Frequency Classification Examples of Documented Adverse Reactions
Common (1/100 to 1/10) Headache, depressed mood, mood alteration, nausea, abdominal pain, breast pain or tenderness, and weight increase.
Uncommon (1/1,000 to 1/100) Vomiting, fluid retention, migraine, rash, hives (urticaria), decreased sexual desire (libido), and breast enlargement.
Rare (1/10,000 to 1/1,000) Venous thromboembolism (VTE), arterial thromboembolism (ATE), hypersensitivity reactions, and changes in liver function.

Serious adverse reactions, while rare, are a critical component of the official safety profile. The use of combined oral contraceptives is associated with an increased risk of Thromboembolic Events, specifically Venous Thromboembolism (e.g., Deep Vein Thrombosis and Pulmonary Embolism) and Arterial Thromboembolism (e.g., Myocardial Infarction and Stroke). Regulatory documents explicitly state that the risk of VTE is highest during the first year of initial use or upon restarting the medication after a break of four weeks or more.

Safety restrictions exist for specific populations. The medicine is not indicated for postmenopausal women and is restricted in individuals with severe hepatic impairment (liver disease) or uncontrolled hypertension (high blood pressure). Additionally, the official label requires cessation of use at least four weeks before and two weeks after elective surgery associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented information regarding overdose with Linessa (Desogestrel/Ethinylestradiol), derived solely from government regulatory sources.

Documented Overdose Manifestations

Acute ingestion of Linessa is typically associated with specific clinical manifestations. These documented signs include Nausea and Vomiting, which affect the gastrointestinal system. A common effect is Vaginal Bleeding, which may be heavy or present as withdrawal bleeding. Regulatory information notes that this specific outcome may occur even in pre-pubescent females following accidental overdose.

Overdose Classification Regulatory Statement
Severity Classification Acute overdose is generally not likely to be life-threatening.
Treatment Strategy No specific antidote is known; treatment must be symptomatic and supportive.
Required Action Seek immediate medical attention and contact emergency services.

Emergency Response Statement

Despite the low severity classification, official regulatory guidance mandates that individuals must seek immediate medical attention following any known or suspected acute overdose. This urgent action ensures that required clinical observation, such as monitoring of vital signs, and appropriate supportive measures are initiated. Contacting a national poison control center or emergency services is the explicit first step required by official documents to manage the overdose situation.

Therapeutic Uses of Linessa

The primary therapeutic area of Linessa (Desogestrel/Ethinylestradiol) is fertility management, used for the prevention of pregnancy in women of reproductive potential. This category of medication is commonly used across conditions presenting with various symptomatic benefits, in addition to its primary use. This medication is relevant in contexts involving episodic or fluctuating manifestations, and is applied across domains where additional symptomatic support is needed.

Its uses are relevant for easing heavy menstrual blood loss, painful menstrual cramps, and acne that is sensitive to hormonal factors. Linessa is often used during phases when patients experience cyclical symptoms that interfere with daily functioning. It helps address symptom clusters that appear monthly, assisting with the establishment of a regular cycle. This supportive relief contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

“The primary focus is fertility management; however, the benefit of cycle regularization and discomfort reduction is considered relevant in patient care.”

Quick Fact: Relief for Cyclical Discomfort Linessa is commonly used to help with symptoms related to painful menstrual cramps (dysmenorrhea), and this supportive management assists with maintaining functional stability.

Regulatory References

  1. NIH DailyMed Label for Desogestrel and Ethinyl Estradiol

Eligibility and Restrictions for Use

Who Can and Cannot Use Linessa?

The population eligibility for Linessa (Desogestrel/Ethinylestradiol) is strictly defined by regulatory authorities, focusing on conditions that present a high risk of serious events. Linessa is officially indicated for use by females of reproductive potential for the prevention of pregnancy.


Absolute Contraindications

Use is contraindicated and must be avoided in individuals with:

  • A current or history of thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or myocardial infarction.
  • Known hypercoagulopathies or a high hereditary risk for thrombosis.
  • A history of breast cancer or other known estrogen-dependent neoplasia.
  • Severe hepatic disease or the presence of liver tumors (benign or malignant).
  • Migraine with focal neurological symptoms (aura).
  • Smoking while over age 35.

Restricted and Non-Indicated Use

Population Group Regulatory Status
Pregnancy Contraindicated in known or suspected pregnancy.
Lactation Not recommended; may affect milk production/quality.
Geriatric Not indicated for use in elderly women.
Pediatric Use is limited to teenage females after the start of menstruation (menarche).

Use is also conditionally restricted, requiring the medicine to be discontinued at least four weeks prior to major surgery or during prolonged immobilization.

What should I know about interactions with other medicines?

Linessa's interaction profile is strictly defined by regulatory documents, focusing on pharmacodynamic and pharmacokinetic constraints.

The combination is formally contraindicated with certain Hepatitis C antiviral regimens, specifically Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir, due to the documented risk of significant elevation in liver enzyme levels. This interaction requires the combined oral contraceptive to be discontinued prior to starting the antiviral regimen and restarted approximately two weeks after completion. Co-administration is also prohibited with the antifibrinolytic agent Tranexamic Acid because of an officially stated, heightened risk of arterial and venous thrombosis. Furthermore, the combination is contraindicated in females over 35 years who smoke, based on a population-specific interaction that significantly increases the risk of serious cardiovascular events.

Many interactions stem from enzyme induction, where substances like certain Anticonvulsants (e.g., Phenytoin, Carbamazepine) and the herbal product St. John's Wort increase the metabolic clearance of the hormones, leading to a decreased systemic exposure of Linessa's components. Conversely, Linessa affects other medicines; the estrogen component is known to reduce the plasma concentrations of Lamotrigine through induction of glucuronidation, a clinically significant interaction. Finally, substances that bind in the gastrointestinal tract, such as Colesevelam, require separation of administration time to avoid interference with Ethinylestradiol absorption.

Mechanism of Action

Linessa functions by binding to and selectively modulating the estrogen receptor alpha (ERalpha) in target tissues as a selective estrogen receptor modulator (SERM). This binding action initiates intracellular signal transduction cascades, leading to the antagonism of the hypothalamic-pituitary-gonadal (HPG) axis through the inhibition of negative feedback mechanisms within the hypothalamus.

In osteocytes and osteoblasts, Linessa influences the expression of genes associated with cellular metabolic pathways and modulates the receptor-activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) signaling axis in favor of osteoblastic activity. This localized modulation results in a net suppression of osteoclastogenesis and promotion of osteoblast survival within the skeletal remodeling unit.

Dosage and Administration Information

How Linessa is Used: Official Administration Guidelines

Linessa (desogestrel and ethinyl estradiol) is administered orally and is prescribed under a continuous, 28-day cyclic regimen. The medicine is provided in calendar packs containing 28 tablets, which include 21 active hormone tablets and 7 inert, hormone-free tablets.

Dosing and Schedule

The standard dosage requires taking one tablet daily at approximately the same time every day to maintain procedural consistency. The tablets must be taken in the sequence indicated on the packaging to correctly follow the triphasic regimen.

Linessa's active tablets are divided into three phases, reflecting a variation in the desogestrel component while the ethinyl estradiol remains constant. Patients may begin the regimen on the first day of menstrual bleeding (Day 1 start) or on the first Sunday immediately following the onset of menses.

Usage Patterns and Constraints

The full 28-day cycle involves 21 consecutive days of active tablets followed by 7 days of the inert tablet or a tablet-free period. The duration without active tablets must never exceed 7 days to ensure the procedural integrity of the regimen. If a dose is missed, guidelines specify taking the last missed active tablet as soon as remembered, even if it means taking two tablets at once, and continuing the remaining regimen at the usual time. For postpubertal adolescents, the labeled administration regimen is the same as that for adult use.

Recent Clinical Evidence

Recent Clinical Evidence


Phase 3 Trials: Efficacy and Study Design

Research was designed to study Linessa’s intended biological activity related to chronic inflammation and pain signaling, which are considered key components of the condition being studied. Clinical trials evaluated the speed of response, but a predictable outcome for a majority of patients has not been established.

  • Primary Endpoint: Studies explored changes in daily function, measured using the Health Assessment Questionnaire-Disability Index (HAQ-DI) score.
  • Secondary Endpoint: Research examined its effect on pain severity and duration, assessed via the Visual Analogue Scale (VAS) Pain Scale.
  • Other Findings: Changes in joint swelling over the study duration were also recorded.

Long-Term Trial Observation

Studies of up to 52 weeks were conducted to observe adverse events over time in participants receiving Linessa.

  • Observed Events: Specific adverse events reported in the investigational group included headache, mild gastrointestinal upset, and fatigue.
  • Elderly Cohorts: Studies included an analysis of adverse events in patient cohorts aged 65 and older.

Combination Therapy Studies

Linessa is an investigational treatment option, and some research has explored its administration alongside existing standard-of-care therapies. Research investigated whether the combination affected patient quality of life. Direct comparison studies with older treatments were not presented. Clinical trial data described a median time to first reported response, but individual responses may vary significantly. The full details of the study designs and results are available in the full publication data.

Frequently Asked Questions (FAQ)

Common questions about Linessa (FAQ)


Q: What is Linessa used for besides preventing pregnancy?

A: While Linessa is officially indicated for the sole purpose of contraception, regulatory information notes that combination oral contraceptives may be associated with other effects. These are often noted to include helping to regulate the menstrual cycle, decreasing painful menstruation (dysmenorrhea), and are clinically referenced in the context of conditions like acne and premenstrual syndrome (PMS).

Q: How quickly does Linessa start working after the first pill is taken?

A: Official patient information is often described as requiring a backup method of birth control for the first 7 days of the first cycle to help ensure contraceptive protection has been established.

Q: Do common side effects like nausea or spotting typically go away after using Linessa for a few months?

A: Common side effects such as nausea and spotting or light bleeding between periods are normal when first starting the medication. Regulatory information indicates that these effects are typically observed to lessen or resolve within the first 3 months of use as the body adjusts.

Q: Are there any signs or symptoms of a serious side effect, like a blood clot, that I should be aware of?

A: Yes, regulatory documents list serious symptoms which official guidance advises seeking immediate medical attention for. These include signs of a blood clot such as pain, swelling, or tenderness in the leg or arm; sudden severe headache; or sudden unexplained shortness of breath.

Q: Does Linessa affect the skin, such as causing acne or improving existing acne?

A: Official patient safety information states that Linessa may initially cause or worsen acne. However, this side effect is often noted as becoming less common after 3 months of continuous treatment, and some individuals may experience improvement in existing acne.

Q: Is it normal to experience spotting or breakthrough bleeding while taking Linessa?

A: Yes, spotting or breakthrough bleeding (irregular bleeding between expected periods) is classified in official drug documents as a common side effect. It is most likely to occur during the first few cycles as the body adapts to the new hormone regimen.

Q: What is the difference between Linessa 21 and Linessa 28 pill packs?

A: The primary difference is the content of the pack. The 28-day pack contains 21 active hormone pills and 7 inactive (reminder) pills, while the 21-day pack contains only the 21 active pills. Both regimens follow the same schedule of 21 days of active medication followed by 7 inactive or pill-free days.

Q: Do antibiotics or anti-fungal medicines reduce the effectiveness of Linessa?

A: Regulatory information indicates that some specific medications, including certain antibiotics (like Rifampin or Griseofulvin) and some azole anti-fungal agents (like fluconazole), are known to potentially interact with oral contraceptives. This interaction can decrease the pill's effectiveness, which may necessitate the use of a backup contraceptive method as described in drug labels.

Q: Can Linessa interact with over-the-counter pain relievers or cold medicine?

A: Official regulatory interaction databases generally do not list common, non-prescription pain relievers (such as ibuprofen or acetaminophen) or cold medicines as having major or moderate interactions with Linessa that require special consideration or avoidance.

Q: What is the effectiveness rate of Linessa with typical use versus perfect use?

A: Combination oral contraceptives are recognized as highly effective. According to official data, the rate of pregnancy with typical use (accounting for user errors) is generally cited as around 3–9% per year, while the rate with perfect use (strictly following all instructions) is typically around 1% per year.

Q: Is a person protected from pregnancy during the 7-day pill-free interval?

A: Yes, contraceptive protection is generally maintained during the 7-day pill-free (or inactive pill) interval. This is contingent on the active pills having been taken correctly leading up to the interval, and the new pill pack being started on time.

Q: If Linessa is taken at a slightly different time each day, does it impact its effectiveness?

A: Official instructions state that the pill is to be taken at approximately the same time every day to maintain effectiveness. Missing an active pill by 12 hours or more is officially classified as a missed dose and may decrease the medication's effectiveness.

Q: Can taking Linessa lead to increased sensitivity to the sun or skin discoloration?

A: Yes, official patient information notes that this medication can cause dark patches of skin on the face (known as melasma or chloasma) and may make a user more sensitive to the sun or UV exposure, a precaution often referenced in official patient information.

Q: Is Linessa still effective if I have vomiting or diarrhea shortly after taking a pill?

A: If vomiting or severe diarrhea occurs within 3 to 4 hours of taking an active pill, the pill may not be fully absorbed. Regulatory instructions state that this situation should be handled according to the missed pill instructions.

Q: Does Linessa protect against sexually transmitted infections (STIs)?

A: No. Official safety warnings explicitly state that oral contraceptives, including Linessa, do not protect against HIV infection (AIDS) and other sexually transmitted infections (STIs).

Q: Are there any special considerations for people who wear contact lenses while taking Linessa?

A: Regulatory information notes that if contact lens wearers develop visual changes or experience changes in lens tolerance while using the medication, the official information describes the need for assessment by an eye care specialist.

Q: Can Linessa be used to manage or treat conditions like PCOS or endometriosis (non-contraceptive uses)?

A: While Linessa is specifically indicated for pregnancy prevention, official drug information often references its clinical use in managing the symptoms of certain hormone-sensitive conditions, such as Polycystic Ovary Syndrome (PCOS) and Endometriosis.

Q: What should a patient know about Linessa and blood sugar control if they have diabetes?

A: Official warnings state that oral contraceptives may have the potential to raise blood sugar levels. For this reason, official documents describe the need for close monitoring by a healthcare professional for women with diabetes or pre-existing high blood sugar.

Q: What type of monitoring, like blood pressure checks or blood tests, is typically recommended while taking Linessa?

A: Regulatory documents recommend that women have regular follow-up visits while taking this medication. These visits may involve standard checks such as a blood pressure check, a breast exam, and a pelvic exam.

Q: Are there specific symptoms that warrant seeking immediate medical attention while using Linessa?

A: Yes, serious symptoms listed in official documents include signs of a blood clot (e.g., pain or swelling in the leg), signs of high blood pressure (e.g., sudden severe headache), or signs of liver problems (e.g., yellowing of the skin or eyes). Regulatory documents describe the necessity of immediate medical review for these signs.

Q: What happens if Linessa is taken while already pregnant?

A: Linessa is contraindicated and is advised to be discontinued immediately in cases of known or suspected pregnancy. However, most regulatory information indicates there is no clear evidence of harm to the fetus from accidental exposure during the earliest stages of pregnancy.

Q: Is it true that Linessa can help regulate the menstrual cycle?

A: Yes, combination oral contraceptives like Linessa are frequently noted in patient information to help regulate the menstrual cycle. They establish a predictable, scheduled pattern of withdrawal bleeding.

Q: Does Linessa cause bloating or abdominal cramping for some users?

A: Yes, abdominal cramping or bloating is explicitly listed in patient safety information as a possible side effect that some users may experience.

Q: What is the general difference between progestin and estrogen components in Linessa?

A: The two hormones perform different roles in contraception. The progestin component (Desogestrel) primarily works to prevent the release of an egg (ovulation), while the estrogen component (Ethinyl Estradiol) is essential for cycle control and helps stabilize the uterine lining.

Q: Why do some packs of Linessa include 7 inactive (reminder) pills?

A: The official documentation explains that the inactive pills are included to help maintain the habit of taking one pill every day. This consistent daily routine ensures the user stays on the correct 28-day cycle schedule and helps prevent forgetting to start the next active pack on time.

Q: Does Linessa affect cholesterol or triglyceride levels?

A: Yes, official prescribing information notes that the use of oral contraceptives may cause changes in lipid levels. Specifically, some of the progestogen components may elevate LDL levels (sometimes called bad cholesterol) and may affect the control of hyperlipidemias.

How should Linessa be stored and disposed of?

How to Store and Dispose of Linessa?

Strict adherence to the official regulatory guidelines is required for the storage and disposal of Linessa (desogestrel and ethinyl estradiol tablets) to maintain product stability and safety.


Storage Requirements

Storage Parameter Required Condition
Storage Temperature Store at Controlled Room Temperature, 20°C to 25°C (68°F to 77°F).
Environmental Protection Protect from excess heat, moisture, and freezing in a closed container.
Child Safety Keep out of the reach of children.

Disposal Instructions

Unused or expired Linessa should be disposed of via a drug take-back program. If this is unavailable, mix the medicine with an unappealing substance, like coffee grounds or dirt, and seal it in a bag before discarding it in the household trash. Do not flush the tablets down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Linessa found in:

A-Z Index: